Theravance Biopharma, Inc. (TBPH)

Market Cap	721.17M
Revenue (ttm)	77.21M
Net Income (ttm)	13.03M
Shares Out	50.36M
EPS (ttm)	0.26
PE Ratio	55.58
Forward PE	28.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	242,264
Open	14.17
Previous Close	14.17
Day's Range	14.15 - 14.35
52-Week Range	7.90 - 15.15
Beta	-0.03
Analysts	Strong Buy
Price Target	23.00 (+60.62%)
Earnings Date	Nov 10, 2025

About TBPH

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 97
• Stock Exchange: NASDAQ
• Ticker Symbol: TBPH
• Website: https://www.theravance.com

Financial Performance

In 2024, Theravance Biopharma's revenue was $64.38 million, an increase of 12.12% compared to the previous year's $57.42 million. Losses were -$56.42 million, 2.22% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for TBPH stock is "Strong Buy." The 12-month stock price target is $23.0, which is an increase of 60.62% from the latest price.

Price Target

$23.0

(60.62% upside)

Analyst Consensus: Strong Buy